+5.6% · 90d
$28.71
+0.08 (+0.28%)
After-Hours $28.71(+0.00)
News
(1)April 2026
Pharvaris N.V. — 20-F Filing
PHVSPharvaris N.V.
# 🧾 What This Document Is This is Pharvaris N.V.'s **Annual Report (Form 20-F)** for the fiscal year ended December 31, 2025. It's a comprehensive filing required by the SEC for foreign companies listed on U.S. exchanges. Think of it as the company's annual "report card" and detailed operational ma
Read summaryView on SEC EDGAR
Peers in Biotechnology
VRTX#1
Vertex Pharmaceuticals Incorporated
$113.64B+0.64%
REGN#2
Regeneron Pharmaceuticals, Inc.
$78.80B-0.99%
ARGX#3
argenx SE
$49.22B+1.97%
ALNY#4
Alnylam Pharmaceuticals, Inc.
$42.61B-1.82%
ONC#5
BeOne Medicines AG
$34.75B+0.39%
INSM#6
Insmed Incorporated
$34.45B-0.37%
RPRX#7
Royalty Pharma plc
$27.86B+0.84%
BNTX#8
BioNTech SE
$23.26B-0.11%
ROIV#9
Roivant Sciences Ltd.
$20.38B+1.10%
MRNA#10
Moderna, Inc.
$20.34B-1.57%